Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 751 of 6351
-
Wolbachia-Infected mosquitoes released to fight dengue, zika, and chikungunya
Prevention Stopped earlyMosquito-borne diseases cause suffering for hundreds of millions of people and claim more than 700,000 lives yearly. Diseases such as dengue, Zika, and chikungunya cause symptoms similar to malaria and are endemic in many parts of the world, yet there are no treatments for them n…
Sponsor: Michigan State University • Aim: Prevention
Last updated Jun 27, 2026 11:03 UTC
-
Can a natural protein fragment help the brain heal after severe injury?
Disease control Recruiting nowThe goal of this clinical trial is to test the safety of the drug Angiotensin (1-7) and learn whether it works well as a treatment in people who have suffered a moderate to severe traumatic brain injury (TBI). The main questions this trial aims to answer are: * Is Angiotensin (…
Phase 1/2 • Sponsor: University of Arizona • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Kangaroo care could slash sepsis risk in tiny newborns
Prevention Recruiting nowNeoDeco is a pragmatic, multicenter, parallel-group, cluster-randomised hybrid effectiveness-implementation trial designed to evaluate the impact of implementing optimised Kangaroo Care (KC) at the unit level compared to standard care in high-technology neonatal units. The trial …
Sponsor: PENTA Foundation • Aim: Prevention
Last updated Jun 27, 2026 12:00 UTC
-
Can a new drug shrink advanced solid tumors?
Disease control Recruiting nowThe study is being conducted to evaluate the safety, tolerability and efficacy of SHR-A2102 for injection with or without Antitumor Therapy in Advanced Solid Tumors. To explore the reasonable dosage of SHR-A2102 for Advanced Solid Tumors.
Phase 1/2 • Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
Can immune booster cells revive failing CAR-T therapy in leukemia?
Disease control Recruiting nowThis is a single-center, double-blind, randomized trial. Patients with relapsed or refractory acute B-lymphoblastic leukemia(r/r B-ALL) experiencing early functional exhaustion of CAR-T cells will be randomly allocated into three groups: the control cell group, the CIK treatment …
Sponsor: Beijing GoBroad Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
Artery plaque scans may reveal hidden stroke risk
Knowledge-focused Recruiting nowThe epidemiology of TOAST classification in Asian patients seems to differ due to the higher rates of large-artery atherosclerosis. The complex pathology of atherosclerosis could lead to recurrent stroke, including shear stress on the endothelium, disturbance of the flow, occlusi…
Sponsor: University Medical Center Ho Chi Minh City (UMC) • Aim: Knowledge-focused
Last updated Aug 08, 2026 00:03 UTC
-
New drug duo takes on tough lymphoma
Disease control Recruiting nowThe phase Ib part of this study aims to determine the recommended phase II dose (RP2D)of linperlisib in combination with chidamide for the treatment of peripheral T-cell lymphoma (PTCL). The phase IIa part is designed to evaluate the preliminary efficacy and safety of the linper…
Phase 1/2 • Sponsor: Yanyan Liu • Aim: Disease control
Last updated Jun 27, 2026 08:02 UTC
-
App aims to turn bystanders into lifesavers against opioid overdoses
Prevention CompletedThe pervasive impact of the opioid epidemic has touched all layers of society for the past two decades, resulting in over 115 deaths daily and imposing annual costs of $78.5 billion. Responding swiftly to overdoses, akin to various medical emergencies, poses a significant challen…
Sponsor: University of Missouri-Columbia • Aim: Prevention
Last updated Aug 21, 2026 00:00 UTC
-
Supercharged immune cells take on childhood cancers
Disease control Recruiting nowPatients may be considered if the cancer has come back, has not gone away after standard treatment or the patient cannot receive standard treatment. This research study uses special immune system cells called CARE T cells, a new experimental treatment. The body has different way…
Phase 1 • Sponsor: Baylor College of Medicine • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
New drug cocktails aim to shrink Hard-to-Treat gut cancers
Disease control Recruiting nowThe purpose of this platform study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of novel RAS(ON) inhibitors combined with Standard(s) of Care (SOC) or with novel agents. The current subprotocols include the following: Subpro…
Phase 1/2 • Sponsor: Revolution Medicines, Inc. • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
Zapping the spine and brain together may restore hand control after paralysis
Symptom relief Recruiting nowWhile physical exercise remains the foundation for any rehabilitation therapy, the team seeks to improve the benefits of exercise by combining it with the concept of "Fire Together, Wire Together" - when brain stimulation is synchronized with spinal cord stimulation, nerve circui…
Sponsor: Bronx VA Medical Center • Aim: Symptom relief
Last updated Jun 27, 2026 07:55 UTC
-
New mRNA flu shot shows promise in early trial
Vaccine CompletedThe purpose of this study is to learn if modified RNA (modRNA) vaccines for the prevention of influenza are: * safe; and * how these vaccines produce an immune response in generally healthy adults. Immune response is the way the body protects itself against things it sees as har…
Phase 1/2 • Sponsor: Pfizer • Aim: Vaccine
Last updated Jun 27, 2026 13:06 UTC
-
New drug shows promise for bulging eyes in thyroid disease
Disease control CompletedThe investigational drug, VRDN-001, is a monoclonal antibody that inhibits the activity of a cell surface receptor called insulin-like growth factor-1 receptor (IGF-1R). Inhibition of IGF-1R may help to reduce the inflammation and associated tissue swelling that occurs in partici…
Phase 3 • Sponsor: Viridian Therapeutics, Inc. • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Hand vs. wrist: which route to the heart is safer during a heart attack?
Disease control CompletedRecently, a novel distal transradial, through anatomical snuffbox, approach has been proposed for undertaking percutaneous coronary angiography and interventions. The existing literature has evaluated distal transradial access (dTRA) as a feasible and safe approach, with faster h…
Sponsor: University Hospital of Patras • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
New hope for hodgkin lymphoma patients unable to tolerate chemo
Disease control Recruiting nowThis is a multicenter, prospective, non-randomized, open-label, phase 2 clinical study to evaluate the efficacy and safety of tislelizumab in patients with de novo Hodgkin Lymphoma deemed ineligible to frontline chemotherapy.
Phase 2 • Sponsor: Fondazione Italiana Linfomi - ETS • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
Aspirin's hidden power against a dangerous pregnancy complication revealed
Prevention By invitation onlyPrimary outcome 1. to identify biological changes in nulliparous women at high risk for preeclampsia defined by combined screening by Fetal Medicine Foundation (FMF) 2. to identify biological effects of aspirin in nulliparous women with high risk for preeclampsia Secondary outc…
Sponsor: Norwegian University of Science and Technology • Aim: Prevention
Last updated Jun 27, 2026 08:03 UTC
-
New targeted pill shows promise for tough lung cancer
Disease control Recruiting nowA first in human study to evaluate the safety and preliminary antitumor activity of BBO-8520, a KRAS G12C (ON and OFF) inhibitor, as a single agent and in combination with pembrolizumab and BBO-10203 in subjects with locally advanced and unresectable or metastatic non-small cell …
Phase 1 • Sponsor: TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Can a gel tame psoriasis? new antibody fragment put to the test
Disease control Stopped earlyA Randomized, Double-Blind, Vehicle-Controlled, Multicenter, Dose-Ranging, Phase 2 Study to Evaluate the Efficacy and Safety of Different Doses of ZL-1102 Topical gel (A Human VH IL-17A Antibody Fragment) in the Treatment of Chronic Plaque Psoriasis
Phase 2 • Sponsor: Zai Lab (Hong Kong), Ltd. • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New hope for brain cancer patients: drug combo targets aggressive tumors
Disease control OngoingThe trial aims to collect safety, efficacy, exposure, dose- response, pharmacokinetic and pharmacodynamic information of the combination of L19TNF and lomustine at different dose levels in patients with Glioblastoma at progression or recurrence
Phase 2 • Sponsor: Philogen S.p.A. • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
HIV kidney transplants: can donor choice reduce rejection?
Disease control Recruiting nowThis research is being done to better understand rejection in transplant recipients with HIV who receive kidneys from donors with vs without HIV.
Sponsor: Johns Hopkins University • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC